Market Overview

UPDATE: JP Morgan Reiterates Baxter International at Overweight; Gambro Expensive but Worth It

Related BAX
Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives & Negatives
Halozyme Therapeutics Receives Favorable FDA Decision
Merck Snags Baxter Executive As CFO (Fox Business)

JP Morgan reiterated its Overweight rating on Baxter International (NYSE: BAX) along with its previous $48 price target.

JP Morgan said, "A $4B purchase price would value Gambro at 2.4x 2011 sales and 12.7x 2011 EBITDA. Extrapolating off the 9 month numbers for 2012 gets you to 2.5x 2012 Revs and 16.3x EBITDA, though again this includes the impact of the Italian quake. By comparison, Baxter trades at 9.7x 2013E EBITDA, with slower growth peers trading at 7-8x. … That said, a Gambro acquisition would (a) allow Baxter to utilize its OUS cash and (b) given the interest currently being earned on this cash and the cost to borrow, the deal would on a cash basis almost certainly be accretive, despite the price tag. It would obviously change in a significant way Baxter's presence in the hemodialysis market, complementing its current leadership in peritoneal dialysis."

Baxter International closed at $58.43 on Friday.

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Most Popular

Related Articles (BAX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters